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Poster Presentation Abstracts 131and can recover to its original shape when compression ratio is less than 80%
which will be very attractive for bone tissue engineering. SEM analysis shows
that the pores in the hydrogel was uniformly present and highly interconnected
which is very important for nutrients transplantation. XRD image indicates that
both polmers and clay were well distributed. Adding macromolecular crosslinker
(PEGDA) into the system can not only increase the biocompatibility but also
improve the bone formation compared with the nanocomposite hydrogel
without PEGDA.
Discussion and Conclusion: A novel nanocomposite hydrogels composed of exfoli-
ated clay showed attractive fracture strain up to 5000% and good compression
strength. This kind of hydrogel was synthesized by in situ photo-polymerization
of monomer in the presence of clay, acrylic acid derivatives and macromolecular
crosslinker (PEGDA). More attractive part is that the obtained nanocomposite
hydrogel has good biocompatibility and can accelerate bone formation. So that
we will explore why this kind of hydrogel can accelerate bone formation and
find out the best PEGDA molecular weight, clay content and solid content for
bone formation.
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MODULATION OF SUPERFICIAL ZONE PROTEIN/LUBRICIN/PRG4 BY
KARTOGENIN AND TRANSFORMING GROWTH FACTOR-b1 IN SURFACE ZONE
CHONDROCYTES IN BOVINE ARTICULAR CARTILAGE
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Introduction: Articular cartilage is an anisotropic structure with a zonal design and
consists of surface or superficial, middle, and deep zones. Superficial zone protein
(SZP)/lubricin/PRG4 functions as a boundary lubricant in articular cartilage to
decrease friction and wear. (Reference 1, 2) As articular cartilage lubrication is
critical for normal joint function, the accumulation of SZP at the surface of carti-
lage is important for joint homeostasis. Recently, a heterocyclic compound called
kartogenin (KGN) was found to induce chondrogenic differentiation and enhance
mRNA expression of lubricin. (Reference. 3) The objective of this study was to
determine whether KGN can stimulate synthesis of SZP in superficial zone articular
chondrocytes and synoviocytes.
Subjects and Methods: We investigated the effects of KGN and transforming
growth factor-b1 (TGF-b1) on articular cartilage and synovium of the bovine
knee joint by evaluating SZP secretion by enzyme-linked immunosorbent assay
analysis. Monolayer, micromass, and explant cultures of articular cartilage, and
monolayer culture of synoviocytes, were treated with KGN and TGF-b1. Explant
was also treated with KGN and IL-1b to evaluate the anti-catabolic effect of
KGN. SZP accumulation in the medium was evaluated and mRNA expression was
measured through quantitative polymerase chain reaction.
Results: TGF-b1 stimulated SZP secretion by superficial zone chondrocytes in
monolayer, explant, and micromass cultures as expected. In addition, SZP secre-
tion was inhibited by IL-1b in explant cultures, and enhanced by TGF-b1 in synovio-
cyte monolayer cultures. Although KGN elicited a 1.2-fold increase in SZP mRNA
expression in combination with TGF-b1, KGN neither stimulated any significant in-
creases in SZP synthesis nor prevented catabolic decreases in SZP production from
IL-1b.
Discussion and Conclusion: These data suggest that the chondrogenic effects of
KGN depend on cellular phenotype and differentiation status, as KGN did not alter
SZP synthesis in differentiated, superficial zone articular chondrocytes. However,
these apparent differences between progenitor and differentiated cell types in
response to KGN merit additional investigation since important new, mechanistic
insights into the effects of KGN may be revealed.
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DIFFERENTIATION THERAPY OF THE NEOPLASTIC STROMAL CELLS IN GIANT
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Background: Giant cell tumor of bone (GCT) is a common neoplasm in Chinese pa-
tients, constituting 20% of all benign bone tumors. The stromal cells of GCT are
widely accepted to be the primary neoplastic cells, and originate from mesen-
chymal stem cells (MSC). Since GCT stromal cells could be induced to be mature
osteoblasts, our research team has proposed the differentiation therapy of GCT
stromal cells. It is noteworthy that rapamycin and simvastatin have been shown
to induce osteogenic differentiation in a number of tumor types, and they are
FDA-approved drugs and have been safely used in patients for decades. Therefore,
we reasoned that they may be developed as adjuvant therapy agents for GCT.
Subjects and Methods: We investigated the effects of rapamycin and simvastatin
on cell viability, proliferation and osteoblastic differentiation in GCT stromal cells
in vitro. Cell viability was assessed using MTT assay, whereas, cell proliferation by
BrdU assay. The markers for assessing the re-differentiation of GCT stromal cells
are ALP, RUNX2, and OCN, and the mRNA level of those markers were detected
by real-time PCR.
Results: Rapamycin decreased the cell viability and proliferation of GCT stromal
cells significantly at 0.05 mM but no further inhibition was observed when
increasing the dose of the drug up to 5 mM. Whereas, simvastatin showed a
dose-dependent inhibition on cell viability and proliferation in GCT stromal cells.
Moreover, the important osteoblastic markers RUNX2 and osteocalcin were up-
regulated by both drugs.
Discussion and Conclusion: Rapamycin and simvastatin inhibited cell viability, and
proliferation of GCT stromal cells. They also stimulated RUNX2 and osteocalcin
gene expression, and may induce differentiation of the tumor cells. Previous
studies have shown that simvastatin induces osteoblast differentiation by moni-
toring Smad signaling and Ras/Rho-mitogen-activated protein kinase pathway
(Yamashita et al. 2008), whereas, rapamycin stimulates the osteoblastic differen-
tiation of human embryonic stem cells by blocking the mammalian target of rapa-
mycin (mTOR) pathway and activating the BMP/Smad pathway (Lee et al. 2010).
The possibility of using rapamycin and simvastatin to promote the differentiation
of GCT stromal cells into mature osteoblasts is appealing. Such a strategy has the
dual advantage of preventing further bone destruction as a result of the osteolytic
tumor while simultaneously promoting bone formation as the neoplastic cells are
differentiated into mature osteoblasts. The mature osteoblasts will eventually un-
dergo apoptosis. It will stop the tumor growth and thus reduce bone resorption.
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EXPRESSION OF GLYPICAN-3 AND PERIOSTIN IN MUSCULOSKELETAL TUMOR
PATIENTS
Thamonwan Woraruthai, Sittisak Honsawek
Chulalongkorn University, Thailand
Background: Glypican-3 (GPC-3) is an extracellular matrix that functions in cell
adhesion, migration and invasion during cell proliferation. It can induce abnormal
cells to apoptosis. Additionally, periostin (POSTN) is also extracellular matrix that
involve in tissue development and regeneration. This gene can bind to integrin for
supporting adhesion and migration of epithelial cells. However, GPC-3 and POSTN
expressions in soft tissue sarcoma remain unclear. The purpose of this study was to
examine expression of GPC3 and POSTN in neoplastic and non-neoplastic adjacent
tissues of musculoskeletal tumor patients.
Subjects and Methods: This research was conducted a cross-sectional study.
Twenty musculoskeletal tumor patients who had liposacroma, osteosarcoma, li-
poma, giant cell tumor and chondroma were enrolled in this study. The GPC-3
132 Poster Presentation Abstractsand POSTN expression were performed by using quantitative real-time polymerase
chain reaction (qRT-PCR).
Results: These findings demonstrated that GPC-3 expression in musculoskeletal tu-
mors was significantly lower when compared to controls (pZ0.02). However,
POSTN expression in musculoskeletal tumor was not significantly different when
compared to that in controls.
Discussion and Conclusion: This study concluded that GPC-3 expression was signif-
icantly lower musculoskeletal tumor patients. Therefore, it can suggest that
neoplastic tissue had down regulated in cell division that causing GPC-3 had lower
expression when compared to that in non-neoplastic adjacent tissue. On the other
hand, POSTN expression in neoplastic tissue seemed to be higher than that in non-
neoplastic adjacent tissues, indicating that neoplastic tissues had abnormal devel-
opment. For further research, larger sample size will be necessary for validating
the results.
http://dx.doi.org/10.1016/j.jot.2016.06.181Session: Disease & Treatment e Ligament, Tendon and Meniscus
299
RELATIVE TELOMERE LENGTH AND MITOCHONDRIA DNA COPY NUMBER IN
LIGAMENTUM FLAVUM OF LUMBAR STENOSIS PATIENTS
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Background: Degenerative lumbar disease is the common cause of low back pain.
In elderly patients, lumbar spinal stenosis is characterized by hypertrophic liga-
mentum flavum (LF), a decrease of elastin-to-collagen ratio, and age-related
fibrosis. Several studies have been reported that the telomere shortening was asso-
ciated with age and degenerative diseases. However, the association between the
telomere length and mitochondria DNA (mtDNA) copy number, and LF of lumbar
spinal stenosis is unknown. Therefore, the purposes of this study were to compare
the relative telomere length (RTL) and mtDNA copy number between non-patho-
logic and pathologic LF from lumbar spinal stenosis patients.
Subjects and Methods: A total of 33 patients with lumbar spinal stenosis were
recruited in the present study. RTL and mtDNA copy number of non-pathologic
and pathologic LF were performed by real-time polymerase chain reaction (qRT-
PCR).
Results: The results showed that pathologic LF tissue had significantly shorter
telomeres than non-pathologic LF tissue (pZ0.004). A significantly shortened
telomere length could be found in pathologic LF tissue within more than 60
years old group as compared to non-pathologic LF tissue (pZ0.023). RTL in path-
ologic LF tissue of female and male groups had significantly shorter telomere
than non-pathologic LF tissue (pZ0.038). Furthermore, there was significant
difference in RTL between female and male within pathologic LF group
(pZ0.27) between two groups, and there was no association in non-pathologic
and pathologic LF tissue between the RTL and mtDNA copy number from lumbar
stenosis patients.
Discussion and Conclusion: This study is the first to examine RTL in ligamentum
flavum of lumbar spinal stenosis patients. Our results showed that patients with
lumbar spinal stenosis displayed an accelerated telomere shortening in pathologic
LF tissue, as compared to non-pathologic LF tissues. The explanation for lower RTL
in pathologic LF tissue may be due to the high turnover rate of cell proliferation. In
accord with this study, Le Maitre et al. reported the mean telomere length was
significantly lower in degenerative disc than non-degenerative disc.
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EZRIN PROMOTES METASTASIS AND INVASION OF OSTEOSARCOMA BY
UPREGULATING lncRNA HOTAIR VIA PI3K/Akt/IRF1 PATHWAY
Jiaming Zhang, Junming Huang, Zhengtao Lv, Fengjing Guo
Tongji Hospital, China
Background: Osteosarcomas are sarcomas of the bone with a high propensity to
metastasize. Ezrin is a member of the ezrin-radixin-moesin (ERM) family of pro-
teins that functions as a cross-linker between the actin cytoskeleton and the
plasma membrane, and plays a vital role in maintaining cell shape and polarity
and facilitates membrane-trafficking pathways, cell migration, cell signaling,
growth regulation, and differentiation. Extensively previous studies had elucidated
that ezrin promotes metastasis of osteosarcoma by activating PI3K/AKT pathway.Furthermore, it has been reported that AKT promotes HOTAIR, which is commonly
overexpressed in osteosarcoma and correlated with poor prognosis, by inhibiting
IRF1 expression in cancer cells. In this manuscript, we try to evaluate the mecha-
nisms of ezrin in promoting the metastasis and invasion of osteosarcoma, and the
relationship between ezrin and HOTAIR.
Subjects and methods: Transwell assays and Wound healing assay were conducted
to detect the influences of ezrin by using inhibitor small interfering RNA(siRNA).
The expression of MMP2/MMP9, AKT, p-AKT, IRF1 and HOTAIR were tested by
real-time PCR (RT-PCR) assays and Western blot. Furthermore, IRFI was knock-
downed and overexpressed to demonstrating the mechanisms of ezrin in regula-
tions of HOTAIR.
Results: The metastasis and invasion of osteosarcoma were suppressed by knock-
down of ezrin. The level of p-AKT and HOTAIR were reduced and IRF1 was upregu-
lated when silencing ezrin. Furthermore, the overexpression of IRF1
downregulated HOTAIR levels in MG63 cells; whereas, the knockdown of IRF1
expression had no obvious effect on HOTAIR expression.
Discussion and Conclusion: Human osteosarcoma usually presented a high ten-
dency to metastatic spread and caused poor outcomes, however, the underlying
mechanism was still largely unknown. Previous efforts had emerged that Ezrin
and HOTAIR are related with these procedures. In this study, we identified the
ezrin promotes metastasis and invasion of osteosarcoma by activating PI3K/AKT
pathway and downregulating IRF1, which binds to the HOTAIR promoter region,
resulting in promoting HOTAIR. Ezrin thus represents a promising target for the
development of novel and effective strategies aimed at preventing the progression
of osteosarcoma.
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DIHYDROMYRICETIN INDUCES WHITE ADIPOSE TISSUE BROWNING AND INHIBITS
OVX AND LPS-INDUCED BONE LOSS
Xuejun Zhang, Yuting Wang, Yonghui Dong, Xin Huang, Anmin Chen, Shilong Huang
Tongji Hospital, Tongji Medical College, Huazhong University of Science and
Technology, China
Background: Dihydromyricetin (DMY), an active small molecule recently discov-
ered from natural medicines, can provide a wide range of health benefits. It was
demonstrated to have anti-inflammatory, antioxidant and anti-tumor effects,
also to improve insulin sensitivity of liver and skeletal muscle in nonalcoholic fatty
liver disease and diabetes. Inflammation and reactive oxygen species (ROS) has an
important role in postmenopausal osteoporosis, so we suppose that DMY also could
reduce inflammatory factors and ROS and inhibit ovariectomized (OVX)-mediated
bone loss.
Subjects and Methods: We used two animal models to test our hypothesis: OVX
and lipopolysaccharide (LPS, 5mg/kg)-induced bone loss models. We injected
DMY (200mg/kg) in intraperitoneally in OVX model for 6 weeks and in calvarial sur-
face in LPS model for 8 days. Bone structure and volume was evaluated by m-CT.
H&E, TRAP and immunohistochemical staining to assess related markers and cell
numbers.
Results: InOVXmodel, we scanning femurwithm-CTat 3weeks in vivo and 6weeks in
vitro, after 3D reconstruction, BV/TV (8.6%), Tb.Th (13%) and Tb.N. (11.6%) signifi-
cantly increased but Tb.Sp (11.6%) decreased compared with sham group, it indi-
cated that DMY could significantly inhibit OVX induced bone loss. H&E and TRAP
staining also show that DMY treat group had fewer osteoclasts number compared
with sham group, and the adipose tissue volume decreased in DMY treat group.
Then we analyst peripheral subcutaneous adipose tissue (SAT, scapular region and
inguinal region), bone marrow adipose tissue (MAT) and visceral adipose tissue
(VAT) by immunohistochemical staining UCP-1, PPARa/g, C/EBPb, both SAT and
VAT has more UCP-1 expressing level than sham group, but PPAR-g, C/EBPb were
down-regulated; In LPS model, the whole calvarial stained with TRAP solution indi-
cated DMY also prevented LPS-induced bone destruction. Serum IL-1, IL-6, TNFa,
and ROS also decreased in both model of DMY group. In vitro study, DMY inhibit
LPS-stimulated RAW264.7 cell proliferation with a dose dependent manner without
influencing the viability of cells by CCK8. DMY also suppressed actin ring formation
and bone resorption and prevents RANKL-induced osteoclasts formation in vitro.
Western-blot and PCR results indicated that DMY down-regulated osteoclast differ-
entiation marker genes c-Fos, NFATc1 in RANKL-induced RAW264.7 cells.
Discussion and Conclusion: Our results indicated that DMY treatment significantly
reduced OVX and LPS-induced bone loss, and also induced WAT browning. We
hypothesised that DMY might induce adipose tissue white-to-brown to inhibit oste-
oclasts differentiation and function, and DMY also might promote osteoblasts dif-
ferentiation and bone formation in vivo. The crosstalk between bone and adipose
tissue and involved signaling pathway and regulatory factors need further
research.
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